Kumai T. et al., focused on inducing an anti-tumour CD4+ response as opposed to CD8+, by combining CD4+ epitope specific peptides with TLR ligands, CD40 monoclonal antibodies and with various co-stimulatory activators to optimise the CD4+ activity (129). Here, CD8A is linked to neoplasm.